Traders Unite!

Aquestive Therapeutics Inc. (NASDAQ: AQST) At Current Prices: Is It Worth Investing In?

view original post

During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)’s traded shares were 0.57 million, with the beta value of the company hitting 3.40. At the end of the trading day, the stock’s price was $1.23, reflecting an intraday gain of 14.95% or $0.16. The 52-week high for the AQST share is $6.40, that puts it down -420.33 from that peak though still a striking 21.14% gain since the share price plummeted to a 52-week low of $0.97. The company’s market capitalization is $54.08M, and the average intraday trading volume over the past 10 days was 0.47 million shares, and the average trade volume was 371.89K shares over the past three months.

Aquestive Therapeutics Inc. (AQST) registered a 14.95% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 14.95% in intraday trading to $1.23 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 1.65%, and it has moved by -44.59% in 30 days. Based on these gigs, the overall price performance for the year is -64.14%. The short interest in Aquestive Therapeutics Inc. (NASDAQ:AQST) is 1.4 million shares and it means that shorts have 3.71 day(s) to cover.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The consensus price target of analysts on Wall Street is $11.00, which implies an increase of 88.82% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $17.00 respectively. As a result, AQST is trading at a discount of -1282.11% off the target high and -469.11% off the low.

Aquestive Therapeutics Inc. (AQST) estimates and forecasts

Statistics show that Aquestive Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Aquestive Therapeutics Inc. (AQST) shares have gone down -80.00% during the last six months, with a year-to-date growth rate less than the industry average at -10.74% against 9.40. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 21.70% this quarter and then drop -2.40% in the quarter after that. In the rating firms’ projections, revenue will increase 7.10% compared to the previous financial year.

Revenue for the current quarter is expected to be $9.36 million as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $10.65 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $7.15 million and $11.12 million respectively. In this case, analysts expect current quarter sales to grow by 30.90% and then drop by -4.20% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -30.60%. While earnings are projected to return -11.80% in 2022.

AQST Dividends

Aquestive Therapeutics Inc. is due to release its next quarterly earnings between March 07 and March 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Aquestive Therapeutics Inc. (NASDAQ:AQST)’s Major holders

Aquestive Therapeutics Inc. insiders own 3.26% of total outstanding shares while institutional holders control 40.54%, with the float percentage being 41.91%. Bratton Capital Management, LP is the largest shareholder of the company, while 71 institutions own stock in it. As of Dec 30, 2021, the company held over 9.81 million shares (or 24.43% of all shares), a total value of $38.16 million in shares.

The next largest institutional holding, with 1.24 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 3.09% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $4.83 million.

Also, the Mutual Funds coming in first place with the largest holdings of Aquestive Therapeutics Inc. (AQST) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.67 million shares. This amounts to just over 1.66 percent of the company’s overall shares, with a $2.91 million market value. The same data shows that the other fund manager holds slightly less at 0.29 million, or about 0.72% of the stock, which is worth about $1.27 million.

Comments are closed.